Avadel Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Avadel Pharmaceuticals PLC
AVDL Stock  USD 8.63  0.21  2.38%   
Avadel Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Avadel Pharmaceuticals PLC investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Avadel Pharmaceuticals financial statements helps investors assess Avadel Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Avadel Pharmaceuticals' valuation are summarized below:
Gross Profit
16.6 M
Profit Margin
(1.12)
Market Capitalization
1.3 B
Enterprise Value Revenue
4.6248
Revenue
95.1 M
There are over one hundred nineteen available fundamental signals for Avadel Pharmaceuticals PLC, which can be analyzed over time and compared to other ratios. We recommend to validate Avadel Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 468.2 M this year, although Enterprise Value will most likely fall to about 201.8 M.

Avadel Pharmaceuticals Total Revenue

177.57 Million

Check Avadel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avadel Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.6 M, Interest Expense of 11.4 M or Selling General Administrative of 190.1 M, as well as many indicators such as Price To Sales Ratio of 7.91, Dividend Yield of 0.0 or PTB Ratio of 14.22. Avadel financial statements analysis is a perfect complement when working with Avadel Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.

Avadel Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets135.8 M164.2 M169.9 M
Slightly volatile
Short and Long Term Debt Total1.6 M1.7 M58.4 M
Pretty Stable
Other Current Liabilities43 M40.9 M24.3 M
Slightly volatile
Total Current Liabilities30.5 M48.8 M39.3 M
Pretty Stable
Property Plant And Equipment Net2 M2.2 M6.6 M
Slightly volatile
Accounts Payable6.3 M7.3 M6.4 M
Slightly volatile
Cash29.2 M51.4 M32.3 M
Slightly volatile
Non Current Assets Total42.8 M30 M56 M
Pretty Stable
Cash And Short Term Investments72.9 M73.8 M89.6 M
Slightly volatile
Net Receivables35.8 M34.1 M13.1 M
Slightly volatile
Common Stock Shares Outstanding99.9 M95.1 M48.1 M
Slightly volatile
Liabilities And Stockholders Equity135.8 M164.2 M169.9 M
Slightly volatile
Non Current Liabilities Total57 M41.6 M87.1 M
Pretty Stable
Other Current Assets4.5 M6 M5.7 M
Slightly volatile
Other Stockholder Equity936.4 M891.8 M456.6 M
Slightly volatile
Total Liabilities87.5 M90.4 M126.4 M
Pretty Stable
Property Plant And Equipment Gross12.5 M13.9 M8.7 M
Very volatile
Total Current Assets93 M134.2 M113.9 M
Slightly volatile
Short Term Debt552.9 K582 K7.2 M
Very volatile
Intangible Assets888.2 K935 K18.1 M
Slightly volatile
Common Stock Total Equity501 K527.4 K1.9 M
Slightly volatile
Common Stock916.8 K965 K2 M
Slightly volatile
Other Liabilities6.3 M6.6 M29.9 M
Pretty Stable
Other Assets10.2 M14.4 M15.5 M
Slightly volatile
Long Term Debt110.6 M105.4 M69.2 M
Slightly volatile
Property Plant Equipment2.2 M2.3 M5.1 M
Slightly volatile
Short Term Investments21.3 M22.4 M62.7 M
Very volatile
Good Will14.3 M15.2 M17.6 M
Slightly volatile
Short and Long Term Debt35.6 M33.9 M41.4 M
Slightly volatile
Long Term Debt Total171.9 M163.8 M70.8 M
Slightly volatile
Capital Surpluse491.4 M631.8 M448 M
Slightly volatile
Non Current Liabilities Other31.8 M35.3 M75.1 M
Slightly volatile
Deferred Long Term Asset Charges8.3 M9.3 M10.1 M
Slightly volatile
Net Invested Capital107.8 M73.8 M111.7 M
Slightly volatile
Net Working Capital112.5 M85.4 M74.5 M
Slightly volatile
Capital Stock720.2 K965 K544.9 K
Slightly volatile
Capital Lease Obligations1.9 M1.7 M2.7 M
Slightly volatile

Avadel Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.6 M2.7 M5 M
Pretty Stable
Interest Expense11.4 M10.8 M7 M
Slightly volatile
Selling General Administrative190.1 M181 M63.8 M
Slightly volatile
Other Operating Expenses222.1 M211.5 M97.7 M
Slightly volatile
Cost Of Revenue16 M15.3 M8.2 M
Pretty Stable
Total Operating Expenses206.1 M196.2 M89.7 M
Slightly volatile
Research Development27.2 M15.2 M24.1 M
Very volatile
Discontinued Operations4.2 M4.6 M4 M
Slightly volatile
Selling And Marketing Expenses1.6 K2.3 K1.7 K
Slightly volatile
Interest Income7.8 M14.4 M10 M
Pretty Stable
Reconciled Depreciation2.3 M2.7 M3.7 M
Slightly volatile
Extraordinary Items234.3 K246.6 K1.9 M
Slightly volatile

Avadel Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow23.2 M31.2 M28.3 M
Slightly volatile
Depreciation4.6 M2.7 M5 M
Pretty Stable
End Period Cash Flow29.2 M51.4 M32.3 M
Slightly volatile
Stock Based Compensation21.4 M20.4 M7.9 M
Slightly volatile
Issuance Of Capital Stock8.8 M9.2 M23.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.915.912714.7252
Slightly volatile
Days Sales Outstanding12573.5905118
Very volatile
Stock Based Compensation To Revenue0.0960.12050.1748
Slightly volatile
Capex To Depreciation0.520.551.1925
Very volatile
EV To Sales7.985.61915.51
Slightly volatile
Inventory Turnover0.720.75261.9918
Slightly volatile
Days Of Inventory On Hand2534851.3 K
Slightly volatile
Payables Turnover1.12.08471.459
Very volatile
Sales General And Administrative To Revenue0.780.870.9535
Slightly volatile
Research And Ddevelopement To Revenue0.08540.08990.5877
Slightly volatile
Capex To Revenue0.00480.0050.07
Slightly volatile
Cash Per Share0.740.77541.9573
Very volatile
Days Payables Outstanding1661751 K
Pretty Stable
Intangibles To Total Assets0.20.10250.2162
Slightly volatile
Current Ratio2.882.74823.8027
Pretty Stable
Receivables Turnover4.114.95995.7363
Very volatile
Capex Per Share0.01020.01070.1479
Pretty Stable
Revenue Per Share1.211.77751.5757
Pretty Stable
Interest Debt Per Share0.130.13171.5536
Very volatile
Debt To Assets0.00990.01040.3456
Very volatile
Graham Number4.512.724.7204
Slightly volatile
Operating Cycle3345591.1 K
Slightly volatile
Days Of Payables Outstanding1661751 K
Pretty Stable
Ebt Per Ebit1.221.15761.2194
Very volatile
Long Term Debt To Capitalization0.01420.0150.4731
Very volatile
Total Debt To Capitalization0.02140.02260.4776
Very volatile
Quick Ratio2.812.33263.701
Pretty Stable
Cash Ratio1.451.0521.1773
Pretty Stable
Days Of Inventory Outstanding2534851.3 K
Slightly volatile
Days Of Sales Outstanding12573.5905118
Very volatile
Fixed Asset Turnover82.478.476624.1832
Slightly volatile
Debt Ratio0.00990.01040.3456
Very volatile
Price Sales Ratio7.915.912714.7252
Slightly volatile
Asset Turnover1.081.02970.4288
Slightly volatile
Gross Profit Margin0.650.90970.8544
Very volatile

Avadel Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap468.2 M445.9 M390.2 M
Slightly volatile
Enterprise Value201.8 M388.4 M339.2 M
Slightly volatile

Avadel Fundamental Market Drivers

Forward Price Earnings36.9004
Cash And Short Term Investments73.8 M

Avadel Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Avadel Pharmaceuticals Financial Statements

Avadel Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Avadel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.1 M-4.9 M
Total Revenue169.1 M177.6 M
Cost Of Revenue15.3 M16 M
Stock Based Compensation To Revenue 0.12  0.10 
Sales General And Administrative To Revenue 0.87  0.78 
Research And Ddevelopement To Revenue 0.09  0.09 
Revenue Per Share 1.78  1.21 
Ebit Per Revenue(0.25)(0.26)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:
How To Invest In Avadel
Details
Is Avadel Stock a good investment?
Details
What is Avadel Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Avadel Pharmaceuticals Correlation against competitors.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.09)
Revenue Per Share
1.036
Quarterly Revenue Growth
26.743
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY